Cuba Leads the Way in Developing New Cancer Drugs

HEALTH, 22 Feb 2016

TeleSur – TRANSCEND Media Service

Dozens of medical products are registered and in testing to improve the quality of life of cancer patients in the long term.

The Cuban health system is one of the most advanced in the world. (photo: EFE)

15 Feb 2016 – Cuba is testing drugs to turn cancer into a manageable chronic disease, adapting treatment to each tumor rather than attacking them with a one-size-fits-all cure.

The island nation is investing in advanced imaging equipment and is preparing to introduce new medical products in 2017 that are currently in trials and development. No less than 28 biopharmaceuticals, mostly therapeutic vaccines and monoclonal antibodies, are already registered or in various stages of testing.

At an international event for nuclear medicine hosted earlier this month in Havana, the director of a radioactive facility announced plans to install a plant that would enhance the treatment of various types of tumors, continuing a strategy of import substitution.

Vaccines that have already made important advances include Heber Provac, used to attack advanced prostate cancer, and CimaVax-EGF against advanced lung cancer. The United States has eyed CimaVax, which can increase life expectancy by seven years, and signed a deal to further test and develop the drug.

While lung cancer is the second-most common cause of death in Cuba, the Caribbean country has a significantly lower prevalence of the disease than the United States, which ranks eighth in the world. Though a poor country, Cuba’s advanced health care system means that Cubans now die of so-called “rich people’s diseases,” reported the BBC, while spending a fraction of the United States on research and care.

WATCH: Blockade Places Restrictions on Cancer Treatment

httpv://www.youtube.com/watch?v=P7yZqq941Ow

Go to Original – telesurtv.net

Share this article: email mastodon facebook 🔗 copy link

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.